var data={"title":"Gadobenate dimeglumine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gadobenate dimeglumine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7794?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gadobenate-dimeglumine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gadobenate dimeglumine: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49334643\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gadolinium-Based Contrast Agents Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is requiring a new class warning, new Medication Guide, and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) regarding gadolinium remaining in patients' bodies, including the brain, for months to years after receiving these drugs. However, because gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, the FDA has concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Health care providers should consider the retention characteristics of each agent when choosing a GBCA for patients who may be at higher risk for gadolinium retention, including those requiring multiple lifetime doses, pregnant women, children, and patients with inflammatory conditions. Although providers should minimize repeated GBCA imaging studies when possible, particularly closely spaced MRI studies, necessary GBCA MRI scans should not be avoided or deferred. Health care providers should ensure that patients carefully read the new Medication Guide before receiving a GBCA.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Further information can be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm&amp;token=Do7F8mUMHZ5/s1VO2ToSVQc0FIvxuJct8s2XQAmrP6Zclph1jTE4ohbEGIUswzhaMGIPSHysMdF12NhZ7JwyN2R2Gou2JaOgN/abp607dqC+GD0vx8r77GARzw9XI5at9GGki/68NHngWSah5+Qw3g==&amp;TOPIC_ID=8955\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm</a>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gadolinium-Based Contrast Agents for MRI Safety Review</span>\n      <span class=\"collapsible-date\">May 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA identified no evidence to date that gadolinium retention in the brain from any of the gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) is harmful, including GBCAs associated with higher retention of gadolinium, and therefore, restricting GBCA use is not warranted at this time. All GBCAs may be associated with some gadolinium retention in the brain and other body tissues. The FDA will continue to assess the safety of GBCAs and plan to have a public meeting to discuss this issue in the future. Health care providers should limit GBCA use to circumstances in which additional information provided by the contrast agent is necessary, and assess the necessity of repetitive MRIs with GBCAs. Retention of gadolinium affects only GBCAs, and does not apply to other types of scanning agents used for other imaging procedures, such as those that are iodine-based or radioisotopes.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery&amp;token=A+6oUwz5nYUZc3lEr1kP7BtLKnUrs6ODZsjcPV9KMyX4JnZOaUZ4v4WHkLmi0EKWvCCQ6RRR7uNYUokCfgeVc768Ba4J+HWDjLlRBCiBxtRZyZ58s7DOgXBX5msP35tg66ICqZf/qPRDl03GsgPnru8Lm2GCbUta4wNEC7od5KHrTCF6F4YU6ugBKJqroXAu&amp;TOPIC_ID=8955\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708883\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrogenic systemic fibrosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with noncontrast-enhanced magnetic resonance imaging (MRI) or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle, and internal organs. The risk of NSF appears highest among patients with chronic, severe kidney disease (glomerular filtration rate [GFR] &lt;30 mL/minute/1.73 m<sup>2</sup>) or acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (eg, &gt;60 years, hypertension, diabetes), estimate the GFR through laboratory testing. For patients at highest risk of NSF, do not exceed the recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413623\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>MultiHance</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26654271\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>MultiHance</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413625\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent;</li>\n      <li>\n        Gadolinium-Containing Contrast Agent;</li>\n      <li>\n        Radiological/Contrast Media (Nonionic, High Osmolality);</li>\n      <li>\n        Radiological/Contrast Media, Paramagnetic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413657\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS lesions (MRI):</b> IV: 0.1 mmol/kg (0.2 mL/kg); may begin imaging immediately after administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal or aorto-ilio-femoral vasculature imaging (MRA):</b> IV: 0.1 mmol/kg (0.2 mL/kg); may begin imaging immediately after administration (calculate scan delay with test bolus [1-2 mL] or with automatic detection technique)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12925803\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>CNS lesions:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants and Children &lt;2 years of age: 0.05 to 0.1 mmol/kg (0.1 to 0.2 mL/kg); may begin imaging immediately after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;2 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3414558\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413658\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Dose adjustment is not recommended; however, use with caution. Risk for NSF development increases as renal function decreases.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo, 2007). Data has shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Kuo, 2007; Okada, 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe, 1998; Kuo, 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413659\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Child-Pugh class B or C: Pharmacokinetics were not significantly altered; dose adjustment is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242654\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MultiHance: 529 mg/mL (5 mL, 10 mL, 15 mL, 20 mL, 50 mL, 100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413624\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51062496\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication;</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MultiHance: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021357s014,021358s013lbl.pdf#page=34&amp;token=KgJQao6U05kIHfTI+RlDJJMRuUO0xEVonBbvnU+WtxH/72o951AonvDpl7UqWbMq3lzRpejJkpEttveFzUHaCwpQrvwzEpE+co0OFXYLhxFH4oalh9maOVQyb/NvcMbI&amp;TOPIC_ID=8955\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021357s014,021358s013lbl.pdf#page=34</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413660\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer as rapid IV bolus injection. To ensure complete injection of medium, flush line with NS after administration using at least 5 mL (for CNS imaging) or at least 20 mL (for renal or aorto-ilio-femoral vasculature angiography). Do not administer other medications in the same IV line.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; initiate hyaluronidase antidote; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Zenk 1981) <b>or</b> injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413626\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS imaging:</b> Magnetic resonance imaging (MRI) agent to visualize CNS lesions in adults and pediatric patients with abnormal blood brain barrier or abnormal vascularity in the brain, spine, and associated tissues</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal and aorto-ilio-femoral vessel angiography:</b> Magnetic resonance angiography (MRA) agent to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174540\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413636\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">1% to 10%:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Central nervous system: Feeling hot (1%), headache (1%)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Gastrointestinal: Nausea (1%), vomiting (&le;1%)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Local: Injection site reaction (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, altered sense of smell, anaphylactic shock, anaphylactoid reaction, anaphylaxis, basophilia, chest pain, chills, diarrhea, dizziness, dysgeusia, dyspnea, ECG abnormality (including PR, QRS, QT, and ST-T segment changes), eye pruritus, facial edema, fatigue, fever, first-degree atrioventricular block, hyperhidrosis, hypersensitivity reaction, laboratory test abnormality (including blood chemistry, hematology, hepatic enzymes, urinalysis), laryngospasm, loss of consciousness, malaise, myalgia, nasal congestion, necrotizing pancreatitis (acute), ocular hyperemia, oral paresthesia, pain, paresthesia, pruritus, pulmonary edema, seizure, shock, sneezing, skin rash, swelling of lips, tongue edema, tremor, urticaria, visual disturbance, weakness, wheezing, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413632\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to gadobenate dimeglumine, any gadolinium-based contrast agent, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413633\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: Cardiac arrhythmias have been observed; use with caution in patients with predisposing proarrhythmic conditions or concurrent proarrhythmic drug therapy. Although average changes in QT<sub>c</sub> compared to placebo were minimal (&lt;5 msec) and no patients experienced malignant arrhythmias, numerically more patients experienced QT<sub>c</sub> prolongation between 30-60 msecs and &ge;61 msecs compared to placebo in one clinical trial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during administration. Avoid extravasation. May cause injection site reactions (local burning/pain, swelling, blistering, and necrosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gadolinium retention: Gadolinium is retained for months or years in brain, bone, skin, and other organs (kidney, liver, spleen); the highest concentration and longest duration have been found in the bone. Linear GBCAs (gadodiamide and gadoversetamide &gt; gadoxetate disodium, gadopentetate dimeglumine, and gadobenate dimeglumine) result in more retention than macrocyclic GBCAs (gadoterate meglumine, gadobutrol, and gadoteridol). Pathologic and clinical consequences of gadolinium retention in skin and other organs have been established in patients with impaired renal function; there also have been rare reports of pathologic skin changes in patients with normal renal function. Consequences of gadolinium retention in the brain or in patients with normal renal function have not been established. Patients with normal renal function that may be at higher risk for gadolinium retention include: patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions; take GBCA retention characteristics into consideration for these patients. Minimize repetitive GBCA imaging studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Anaphylactic and anaphylactoid reactions (some fatal) have occurred (with cardiovascular, respiratory or dermatologic involvement); symptoms typically occurred within minutes of administration. Monitor patients closely during and for up to 2 hours after infusion. If hypersensitivity occurs, begin immediate management. Appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Delayed reactions may also occur (within several hours of administration). Patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions; use caution in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrogenic systemic fibrosis: <b>[US Boxed Warning]: Gadolinium-based contrast agents (GBCAs) exposure increases the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA enhanced imaging is essential for diagnostic purposes. The risk is highest in patients with acute kidney injury or chronic, severe renal disease (glomerular filtration rate [GFR] &lt;30 mL/minute/1.73 m<sup>2</sup>). NSF may result in debilitating or fatal systemic fibrosis; affects the skin, muscle, and internal organs. Prior to administration, screen all patients for acute kidney injury or other conditions which may reduce renal function; estimate GFR in patients at risk for chronic declines in renal function (eg, age &gt;60, chronic hypertension, diabetes). Do not exceed the recommended dose and allow a sufficient interval between readministration in patients at risk for NSF.</b> The risk for NSF appears lower in patients with moderate, chronic renal disease (GFR 30 to 59 mL/minute/1.73 m<sup>2</sup>) and little, if any, in patients with mild, chronic renal disease (GFR 60 to 89 mL/minute/1.73 m<sup>2</sup>). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration. If NSF occurs, report to manufacturer or the Food and Drug Administration (FDA).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Metabolic disorders: May prolong systemic exposure with some drugs (eg, cisplatin, anthracyclines) due to competition for certain multispecific organic anion transporters (MOAT) especially in patients with decreased MOAT activity (eg, Dubin Johnson syndrome).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency following use of other gadolinium agents, generally within 48 hours following administration. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Scan interpretation: Certain lesions may not appear with contrast-enhanced scan that do appear with noncontrast imaging; use caution when interpreting.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299375\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413643\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8955&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413628\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Gadolinium-based contrast agents cross the placenta; in general, their use in pregnant women is controversial (ACOG 2017). Use should be avoided unless critical for the care of the mother or fetus and it is not prudent to wait until after pregnancy. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413631\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gadobenate dimeglumine is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Product labeling notes that a breastfed infant may be exposed to 0.001 to 0.04% of the maternal dose (limited data). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Because of the low expected excretion into breast milk and the low absorption from an infant's GI tract, other sources note that breastfeeding may be continued without interruption after use (ACOG 2017; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding can pump and store milk prior to the procedure and abstain from breastfeeding for 12 to 24 hours (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413663\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs of hypersensitivity (during and for several hours after procedure); renal function (prior to administration); short- and long-term monitoring of signs and symptoms of NSF (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413649\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Gadobenate dimeglumine is a gadolinium-containing paramagnetic agent. Exposure to an external magnetic field induces a large local magnetic field in exposed tissues. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3413651\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.17-0.282 L/kg; Distribution half-life: 0.084-0.605 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Gadobenate and dimeglumine dissociate after injection; pharmacokinetics are based on gadobenate; there is no additional biotransformation of gadobenate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Normal renal function: ~1-2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30-60 mL/minute: ~6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10-30 mL/minute: ~9.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (without dialysis): ~42 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (78% to 96%); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322910\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (MultiHance Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">529 mg/mL (15 mL): $102.14</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038314\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Multihance (AT, AU, BE, CH, CN, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IL, IT, KR, LU, NL, NO, NZ, PH, PL, PT, RO, SE, SG, SI, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28937575\"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion No. 723: Guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216. doi: 10.1097/AOG.0000000000002355.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobenate-dimeglumine-drug-information/abstract-text/28937575/pubmed\" target=\"_blank\" id=\"28937575\">28937575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Nephrogenic Fibrosing Dermopathy Associated With Exposure to Gadolinium-Containing Contrast Agents -- St. Louis, Missouri, 2002-2006,&rdquo; <i>MMWR Weekly Rep</i>, 2007, 56(7):137-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobenate-dimeglumine-drug-information/abstract-text/17318112/pubmed\" target=\"_blank\" id=\"17318112\">17318112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grobner T, &ldquo;Gadolinium - A Specific Trigger for the Development of Nephrogenic Fibrosing Dermopathy and Nephrogenic Systemic Fibrosis,&rdquo; <i>Nephrol Dial Transplant</i>, 2006, 21(4):1104-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobenate-dimeglumine-drug-information/abstract-text/16431890/pubmed\" target=\"_blank\" id=\"16431890\">16431890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joffe P, Thomsen HS, and Meusel M, &quot;Pharmacokinetics of Gadodiamide Injection in Patients with Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis,&quot; <i>Acad Radiol</i>, 1998, 5(7):491-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobenate-dimeglumine-drug-information/abstract-text/9653466/pubmed\" target=\"_blank\" id=\"9653466\">9653466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuo PH, Kanal E, Abu-Alfa AK, et al, &quot;Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis,&quot; <i>Radiology</i>, 2007, 242(3):647-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobenate-dimeglumine-drug-information/abstract-text/17213364/pubmed\" target=\"_blank\" id=\"17213364\">17213364</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME, &quot;Extravasation: A Hazard of Intravenous Therapy,&quot; <i>Drug Intell Clin Pharm</i>, 1983, 17(10):713-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobenate-dimeglumine-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MultiHance (gadobenate dimeglumine) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Okada S, Katagiri K, Kumazaki T, et al, &ldquo;Safety of Gadolinium Contrast Agent in Hemodialysis Patients,&rdquo; <i> Acta Radiol</i>, 2001, 42(3):339-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobenate-dimeglumine-drug-information/abstract-text/11350296/pubmed\" target=\"_blank\" id=\"11350296\">11350296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pirovana G, Goodman DB, Halemane U, et al, &ldquo;Cardiac Electrophysiologic Monitoring After Injection of Gadobenate Dimeglumine Versus Placebo in Healthy Volunteers and Patients with Cardiovascular Disease,&rdquo; <i>Cardiac Electrophys Monit</i>, 2004, 233(2):555-65.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J, &quot;Extravasation of Contrast Media Managed With Recombinant Human Hyaluronidase,&quot; <i>Am J Emerg Med</i>, 2012, 30(9):2102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobenate-dimeglumine-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wanko SO, Telen MJ, &ldquo;Transfusion Management in Sickle Cell Disease,&rdquo; <i>Hematol Oncol Clin N Am</i>, 2005, 19(5):803-26.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Webb JA, Thomsen HS, and Morcos SK, &quot;The Use of Iodinated and Gadolinium Contrast Media During Pregnancy and Lactation,&quot; <i>Eur Radiol</i>, 2005, 15(6):1234-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobenate-dimeglumine-drug-information/abstract-text/15609057/pubmed\" target=\"_blank\" id=\"15609057\">15609057</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Widmark JM, &ldquo;Imaging-related Medications: A Class Overview,&rdquo; <i>Proc (Bayl Univ Med Cent)</i>, 2007, 20(4):408-17.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE, &quot;Management of Intravenous Extravasations,&quot; <i>Infusion</i>, 1981, 5(4):77-9.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8955 Version 119.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F49334643\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708883\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3413623\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F26654271\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3413625\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3413657\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F12925803\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3414558\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F3413658\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F3413659\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F242654\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3413624\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F51062496\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3413660\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3413626\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174540\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3413636\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3413632\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3413633\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299375\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F3413643\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3413628\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3413631\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3413663\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3413649\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3413651\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322910\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038314\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8955|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gadobenate-dimeglumine-patient-drug-information\" class=\"drug drug_patient\">Gadobenate dimeglumine: Patient drug information \t</a></li></ul></div></div>","javascript":null}